& Media

Leading with purpose. Every day.

Ultragenyx is a biopharmaceutical company committed to bringing to patients novel products for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.

The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.

Data Provided by Refinitiv. Minimum 15 minutes delayed.

May 17, 2024

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Read more
May 7, 2024

Ultragenyx to Participate at Bank of America’s 2024 Healthcare Conference

Read more
May 2, 2024

Ultragenyx Reports First Quarter 2024 Financial Results and Corporate Update

Read more
Sign up for Email Alerts
Email Alerts Sign-up